Gene · 2213
NIH grants2,625
NIH grants whose papers are about the gene, through NIH's grant-paper links.
261 to 280 of 2,625
Download this page as JSON| Grant | Title | FCGR2B papers | Newest fiscal year |
|---|---|---|---|
| R01AI174979 | Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization | 1 | 2025 |
| R01AI176646 | Understanding and optimizing antibody-based interventions against neonatal HSV infection | 1 | 2025 |
| R01AI186809 | Targeting the HIV-1 reservoir at cART initiation with CD4-mimetic interventions | 1 | 2025 |
| R01AI186995 | Molecular characterization and modeling efficient antibody effector function | 1 | 2025 |
| R01AR043369 | MITF from control of pigmentation to melanoma risk | 1 | 2025 |
| R01AR051749 | Complement in the Pathogenesis of Autoimmune Arthritis | 1 | 2025 |
| R01AR063759 | Defining the influence of RA genetic susceptibility factors on T cell antigen specificity and functional state | 1 | 2025 |
| R01AR072304 | Therapeutic strategies for treatment of giant congenital melanocytic nevi | 1 | 2025 |
| R01AR073201 | Bridging the gap between GWAS and mechanism in arthritis | 1 | 2025 |
| R01AR074096 | Monitoring Disease in Lupus | 1 | 2025 |
| R01AR077534 | Studies of Osteoclast Lineage in Health and Diseases | 1 | 2025 |
| R01CA197916 | Targeting the liver for immunotherapy in pancreatic cancer | 1 | 2025 |
| R01CA254104 | Investigating Macrophage Molecular and Functional Diversity in Tumor Immunity | 1 | 2025 |
| R01CA255250 | Identifying and engaging a universal adjuvant for breaking macrophage immune tolerance in cancer | 1 | 2025 |
| R01CA257195 | Deciphering the molecular control of intratumoral dendritic cells | 1 | 2025 |
| R01CA258882 | Role of the complement C3a receptor on immune and non immune intestinal barrier functions and microbiota in colorectal cancer development | 1 | 2025 |
| R01CA263079 | Reprogramming myeloid cells to inhibit cancer development | 1 | 2025 |
| R01CA265095 | Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | 1 | 2025 |
| R01CA266457 | Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors | 1 | 2025 |
| R01CA266612 | Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2213/grants?page=14